Search results
Showing 16 to 30 of 34 results for bandage
Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)
NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .
NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .
NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds
Dupilumab for treating moderate to severe atopic dermatitis (TA534)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults.
NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .
Ultrasound-guided foam sclerotherapy for varicose veins (HTG301)
Evidence-based recommendations on ultrasound guided foam sclerotherapy for varicose veins. This involves mixing a chemical with air or another gas to produce a foam, which is injected into the affected vein using ultrasound imaging to monitor its progress.
View recommendations for HTG301Show all sections
Sections for HTG301
Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.
NICE has developed a medtech innovation briefing (MIB) on the Quantitative Timed Up and Go (QTUG)
Boston Keratoprosthesis Type I for corneal blindness (MIB91)
NICE has developed a medtech innovation briefing (MIB) on Boston Keratoprosthesis Type I for corneal blindness .
Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.
Birch bark extract for treating epidermolysis bullosa (HST28)
Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.
L-Dex U400 for lymphoedema after breast cancer treatment (MIB111)
NICE has developed a medtech innovation briefing (MIB) on L-Dex U400 for lymphoedema after breast cancer treatment .
This quality standard covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It describes high-quality care in priority areas for improvement.
View quality statements for QS208Show all sections
Sections for QS208
- Quality statements
- Quality statement 1: Structured education programmes
- Quality statement 2: Continuous glucose monitoring
- Quality statement 3: Statin therapy for primary prevention of cardiovascular disease
- Quality statement 4: 9 key care processes
- Quality statement 5: Assessing the risk of diabetic foot problems on admission to hospital
- Quality statement 6: Support to self-manage diabetes during inpatient admissions
- Quality statement 7 (placeholder): Identification of eating disorders in adults with type 1 diabetes
NICE has developed a medtech innovation briefing (MIB) on EpiFix for chronic wounds .
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.